MAVENIR
27.2.2024 10:50:33 CET | Business Wire | Press release
solutions by stc, the leading enabler of digital transformation in Saudi Arabia and the region, announces an Open RAN agreement with Mavenir, the cloud-native network infrastructure provider building the future of networks, to launch the first commercial Open RAN network in Saudi Arabia. The announcement is a boost to stc’s Group strategic mission to deliver emerging technology to the Kingdom’s mobile customers, supporting the Vision 2030 digital transformation strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226664170/en/
Signing ceremony at Mobile World Congress (MWC) on stc stand in Hall 3. Executive company representatives: Yousef Almarshad, Chief Commercial Officer at solutions by stc & Pardeep Kohli, Chief Executive Office at Mavenir. (Photo: Business Wire)
The service is expected to go-live commercially with its next-generation Open RAN network in 2024, this decision follows a successful initial deployment for multi-layer 4G and 5G NSA Access Network on the Open RAN platform to stc, delivered in partnership with solutions by stc and Mavenir.
The newly launched multi-layered 4G and 5G Radio network will utilize Mavenir’s 4G Remote Radio Unit (RRU) and 5G Massive MIMO (mMIMO) Active Antenna Unit (AAU) technology and leverage the cloud-native Mavenir Webscale Platform (MWP) with fully containerized Centralized Unit (CU) and Distributed Unit (DU) software. The solution will run on x86 commercial-off-the-shelf (COTS) hardware platform that represents best-in-class technology for open interface radio systems. Mavenir and Saudi Arabia-based partner solutions by stc will provide stc with a cloud-native deployment solution that harnesses a full combination of expert professional services plus cutting-edge hardware and software and seamlessly integrated into stc’s radio network.
Yousef Almarshad, Chief Commercial Officer of solutions by stc commented: “Mavenir’s Open RAN technology innovation, together with solutions by stc unrivalled experience in the Saudia Arabia market, provide a strong foundation for this trail-blazing Open RAN deployment, bringing the next-generation performance and breakthrough services to stc’s valued customers across the Kingdom – going beyond data speeds to a more sustainably, securely and cost-effective network powered by Mavenir’s Open RAN.”
BG Kumar, President, Access Networks, Platforms and Digital Enablement at Mavenir, added: “Mavenir is extremely pleased to be awarded with the opportunity to build the first commercial Open RAN deployment in Saudi Arabia in collaboration with solutions by stc. Mavenir is confident that stc’s Open RAN network in Saudi Arabia will act as a catalyst for further accelerating operators’ digital transformation journeys across the Middle East region, ushering in a wave of customer-focused innovation that can fully leverage the unique potential generated by open standards and architecture.”
About stc Group:
stc group is an engine of digital transformation in the region, offering advanced solutions and driving the digitisation process. The group offers landline and fixed infrastructure, mobile and data services, and broadband & cloud computing services. www.stc.com.sa
About solutions by stc:
solutions by stc represents the driving force of digital transformation in the Kingdom of Saudi Arabia and the region, and the number one provider of information technology solutions in Saudi.
solutions aims to empower the public and private sectors by meeting the requirements of the digital age and adopting its latest trends. It also works to provide its customers with a diverse portfolio of services and products to support their daily operations, as the basic communications and information technology services provided by the company are designed to enable management and expansion of business.
solutions by stc started its operations more than 25 years ago and has provided its services to nearly 24,000 clients in 35 cities in Saudi Arabia and the region. The company's experience spans across several key sectors, including banking, healthcare, education, oil and gas, real estate, and telecom. The company has approximately 1,700 employees, including more than 1,000 with certifications in core technology areas. www.solutions.com.sa
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com
Meet Mavenir at Mobile World Congress 2024 (Barcelona, Feb 26 – 29 2024)
To explore our latest innovations, MWC show announcements and learn more about how Mavenir is delivering the Future of Networks – Today, visit our team in Hall 2 (Stand 2H60).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240226664170/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom